UM News

Previous Articles
2014
January
February
March
April
May
June
July
August
September
October
November
December
2013
January
February
March
April
May
June
July
August
September
October
November
December
2012
January
February
March
April
May
June
July
August
September
October
November
December

UMB creates position to encourage research, industry partnerships

Simeon Taylor, MD, PhD, a seasoned pharmaceutical executive who has served in senior positions with Eli Lilly and Co. and Bristol-Myers Squibb, has joined the University of Maryland, Baltimore (UMB) as industry liaison with its Center for Clinical Trials and Corporate Contracts (CCT).

In his new role for CCT, he will assist faculty in developing research strategies that will maximize corporate partnering and funding opportunities, and the possible creation of valuable intellectual property. CCT is part of the University's Office of Research and Development, and the part-time consultancy is funded in keeping with the University's 2011-2016 Strategic Plan.

"We are delighted to add Simeon to CCT's business development team. We created the industry liaison position to maximize our corporate partnering and funding opportunities with the hope that this research may lead to new, valuable intellectual property," says Michael Rollor, PhD, MBA, assistant vice president at CCT.

"Simeon understands the academic research environment and is also able to provide valuable insights and contacts drawn directly from his experience as a pharmaceutical executive," Rollor says.

Taylor brings experience in both industry and government. In 1979, he went to the U.S. National Institutes of Health, where he was chief of the Diabetes Branch from 1989 to 2000. At NIH, his research focused on mechanisms of insulin resistance, genetics of insulin resistant diabetes, and devising innovative therapies including metreleptin to treat lipoatrophic diabetes.

His contributions were recognized with the Outstanding Service Award of the U.S. Public Health Service and the Outstanding Scientific Achievement Award of the American Diabetes Association.

In 2000, Taylor moved to the pharmaceutical industry. In his role as vice president of cardiovascular and metabolic disease research at Bristol-Myers Squibb, he made substantial contributions to research and development, leading to three approved drugs: saxagliptin, dapagliflozin, and apixaban.

Most recently, he has returned to academia as an adjunct professor in the Division of Endocrinology, Diabetes and Nutrition at the University of Maryland School of Medicine.

Taylor received his education at Harvard University (BA, MD, and PhD) and his clinical training at Massachusetts General Hospital (Internal Medicine and Endocrinology).
Posting Date: 05/30/2014
Contact Name: Patricia Fanning
Contact Phone: 410-706-7946
Contact Email: pfanning@umaryland.edu